In Brief: Genetics Institute's BeneFix
Executive Summary
Genetics Institute's BeneFix: Recombinant factor IX product review status will be discussed at FDA Blood Products Advisory Committee meeting on Dec. 12 at 8 a.m. at Bethesda, Md. Holiday Inn. FDA proposal on limiting plasma pool size for fractionated plasma products also will be reviewed. In addition, the committee will consider safety and efficacy of solvent detergent plasma from the New York Blood Center...